Results 121 to 130 of about 24,113 (230)

Use of FK506 Immunosuppressive Therapy in Pancreas Transplantation

, 1996
The purpose of this study was to evaluate the safety, efficacy, and transplant outcomes associated with FK506 rescue and maintenance therapy in pancreas transplant recipients.
Rita Alloway, Debra S Elmer, Donna K Hathaway, Trine Nyman, AO Gaber   +4 more
core   +1 more source

FK506 and protein kinase C [PDF]

Nature, 1991
M, Tropschug, R, Hofmann
openaire   +2 more sources

Formal total synthesis of (-)-FK506

, 1992
FK506 (2)* was isolated in 1987 by Fujisawa Pharmaceutical Co. in Japan from a strain of Streptomyces tsukubanesis (no. 9993). FK506 has been shown to be more potent than Cyclosporin A (1, CsA), the only anti-rejection drug currently used.
Chen, Kwunmin
core  

The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae

, 1993
The immunosuppressants cyclosporin A, FK506, and rapamycin inhibit growth of unicellular eukaryotic microorganisms and also block activation of T lymphocytes from multicellular eukaryotes. In vitro, these compounds bind and inhibit two different types of
Hall, M. N., Movva, N. R., Koller, A., Schmidt, A., Kunz, J., Henriquez, R., Heitman, J.   +6 more
core  

Tacrolimus (FK506) in Thoracic Organ Transplantation

Tacrolimus (FK506) was discovered as the result of a systematic screening program to look for an improved immunosuppressant. In the mid-1980s Goto and associates from the Exploratory Research Laboratories of Fujisawa Pharmaceutical Co.
Pham, S. M., Gammie, J. S.
core   +1 more source

Aneuploidy promotes transient stress adaptation and metabolic flexibility in the human fungal pathogen Aspergillus fumigatus. [PDF]

Curr Biol
Lehmann AE, Aguilar Ramírez E, Keller NP, Heitman J.   +3 more
europepmc   +1 more source

FK506: the promise and the paradox

Clinical and Experimental Immunology, 1991
openaire   +3 more sources

Retraction Note: FK506-binding protein-5 in high-fat diet-induced metabolic dysfunction-associated steatotic liver disease. [PDF]

Sci Rep
Wu LL, Liao YJ, Peng WH, Chen LK, Huang YC, Chen CY, Juan CC.   +6 more
europepmc   +1 more source

Tacrolimus (FK506) Cerebral Blindness Following Translplantation

, 1995
Tacrolimus (FK506) is an immunosuppressant agent in use since 1984 to prevent graft rejection following transplantation. It is presumed similar to cyclosporine in its mode of action and its toxicity.
Todd C. Geis, MD; Nancy J. Newman, MD
core  

Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease. [PDF]

Mater Today Bio
Liu L, Chen D, Sheng S, Lin X, Zhao H, Liu C, Chen X, Ye Y, Xu W.   +8 more
europepmc   +1 more source